{"entity":{"id":"nct07527858","kind":"trial","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of Nivolumab, Bevacizumab in colorectal cancer, run by Gilead Sciences, now recruiting.","summary":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07527858 by Gilead Sciences, with 170 participants planned, started 2026-05-19 and due to reach its primary completion in 2028-12. Interventions recorded: Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil. Conditions listed: Advanced Microsatellite Stable Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07527858","url":"https://clinicaltrials.gov/study/NCT07527858"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","bevacizumab"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07527858","phase":"2","setting":"A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)","sponsor":"Gilead Sciences","enrolled":170,"outcomes":[]},"route":"/trials/nct07527858/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}